OBJECTIVES The purpose of this study was to investigate the effect of the RenalGuard System (PLC Medical Systems, Milford, Massachusetts) on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve replacement (TAVR).
A cute kidney injury (AKI) is a frequent complication of contrastguided interventional procedures (1, 2) . Not surprisingly, transcatheter aortic valve replacement (TAVR) is also associated with varying degrees of post-procedural AKI, ranging from 12% to 57%, which carries a negative prognostic effect (3) (4) (5) (6) (7) (8) . Preventive intravenous hydration with isotonic saline solution is known to decrease the risk of AKI (9, 10) . However, in patients with impaired left ventricular function and left side valvular heart diseases, hydration is usually suboptimal due to the perceived risk of overhydration and pulmonary edema. In previous studies, diuretic agents have been combined with hydration to increase urine output and prevent overhydration (11) (12) (13) .
The RenalGuard System (PLC Medical Systems, Barbanti et al. 
FIGURE 2 Study Flow Chart
A total of 112 patients were randomized and assigned to either the RenalGuard group (n = 56) or the control group (n = 56) with no crossover.
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administration of the contrast agent; and before discharge.
SAMPLE SIZE CALCULATION. Averaging the 12% and 57% AKI rates post-TAVR reported by the available published data (4, 5, 19, 20) and the AKI rate in the REPLACE registry before trial initiation (30%), we anticipated that the overall rate of AKI in the control group would be 28%. Assuming an incidence of 8% of overall rate of AKI in the RenalGuard group, a sample size of 110 patients (55 patients per group) provided 80% power to detect statistically significant differences in AKI at a 2-sided alpha of 0.05. Table 1 . An estimated glomerular filtration rate <60 ml/m calculated by the Cockcroft-Gault and the Modification of Diet in Renal Disease formulas was reported in 74 patients (66.1%) and 50 patients (44.6%), respectively. A total of 64 patients (57%) had moderate predicted risk to develop a contrastinduced AKI according to the Mehran risk score, with no differences between study groups (Figure 3) . PROCEDURAL OUTCOMES. Procedural data are shown in Table 2 . VARC-defined device success was obtained in 107 patients (95.5%), with no differences between the 2 groups. Also, no differences in terms of contrast dye administered were observed. Table 3 . A significant increase in Values are n (%) or median (interquartile range). *Valve-in-valve: implantation of a second prosthesis inside the first one to treat the first valve's malposition during the index procedure. †Valve-on-valve: implantation of a second valve in its anatomical position after embolization in ascending aorta of the first valve deployed.
PCI ¼ percutaneous coronary intervention.
FI GURE 4 Study Primary Endpoint
Incidence of acute kidney injury (AKI) stages 1 and 3 in the study population. CI ¼ confidence interval; RR ¼ relative risk.
Barbanti et al. Length of in-hospital stay (from TAVR to discharge) was similar in the 2 groups (RenalGuard group 3.5 AE 4.1 days vs. control group 3.5 AE 3.5 days; p ¼ 0.940). VARCdefined in-hospital outcomes and 30-day outcomes are listed in Table 4 . No significant differences in terms of mortality, cerebrovascular events, bleeding, vascular complications, and re-hospitalization for heart failure were noted between groups.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S
PREDICTORS OF AKI. At the multivariable analysis, procedures performed without the RenalGuard System (adjusted odds ratio: 5.99, 95% CI: 1.56 to 23.04; p ¼ 0.009) and AKI risk score 4 (adjusted odds ratio: 4.31, 95% CI: 1.39 to 13.37) were found to be independently associated with an increased risk of AKI.
DISCUSSION
Baseline renal function should be kept in mind in elderly and sick patients, such as those with severe aortic stenosis, because post-operative AKI seems to significantly worsen the early and late prognosis of those undergoing TAVR (19, 21) . Despite the widespread utilization of this procedure, no standardized protocol for AKI prevention has been proposed yet.
The results of this single-center randomized study powered to detect differences in AKI within 72 h after TAVR demonstrate that prophylactic intravenous loading dose of 250-ml normal saline solution combined with furosemide-induced high-volume diuresis Variation in creatinine value in response to contrast dye administered in the 2 groups. In-hospital WHAT IS NEXT? Furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
